Published in J Hepatol on February 01, 2001
Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect (2004) 1.78
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend (2012) 1.37
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09
Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Int J Drug Policy (2011) 0.90
Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J Addict Med (2010) 0.87
A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med (2014) 0.86
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil (2015) 0.84
Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction (2012) 0.81
Mitochondria: important target for drug toxicity? J Hepatol (2001) 0.78
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. J Subst Abuse Treat (2016) 0.75
Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. Drug Alcohol Depend (2014) 0.75
Buprenorphine: a (relatively) new treatment for opioid dependence. Psychiatry (Edgmont) (2005) 0.75
Fulminant hepatic failure after intravenous injection of sublingual buprenorphine in a patient with hepatitis C. Clin Case Rep (2015) 0.75
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 5.38
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med (1997) 3.49
Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology (2000) 3.16
Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med (2001) 2.95
Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology (2001) 2.75
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 2.63
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology (1995) 2.54
Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis (1986) 2.39
Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology (1991) 2.38
Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology (2000) 2.34
Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol (1999) 2.33
Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology (2000) 2.21
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet (1991) 2.14
Steatosis in chronic hepatitis C: why does it really matter? Gut (2006) 2.10
Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med (2000) 2.08
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Genetic influences on the end-stage effector phase of arthritis. J Exp Med (2001) 1.99
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut (2006) 1.95
An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology (1999) 1.92
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology (2001) 1.87
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol (2005) 1.85
Second generation (RIBA) test in diagnosis of chronic hepatitis C. Lancet (1991) 1.84
Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study. Ann Intern Med (1991) 1.84
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 1.84
Do women physicians do more STD prevention than men? Quebec study of recently trained family physicians. Can Fam Physician (1997) 1.80
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther (1995) 1.78
Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med (1985) 1.75
Epithelioid hemangioendothelioma, multiple focal nodular hyperplasias, and cavernous hemangiomas of the liver. Arch Pathol Lab Med (1999) 1.71
Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology (1998) 1.69
Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology (1994) 1.69
Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut (2002) 1.68
Abdominal wall hernias in the setting of cirrhosis. Semin Liver Dis (1997) 1.67
A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology (2000) 1.67
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut (2005) 1.65
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology (1993) 1.64
Serum p53 antibodies as early markers of lung cancer. Nat Med (1995) 1.63
Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut (2000) 1.63
Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology (1985) 1.62
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 1.61
Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology (1997) 1.61
Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol (2001) 1.61
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology (1998) 1.58
Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol (1994) 1.56
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut (2009) 1.56
Emergency liver transplantation for fulminant hepatitis. Ann Intern Med (1987) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res (1995) 1.54
Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology (1994) 1.54
In situ split liver transplantation for two adult recipients. Transplantation (2000) 1.53
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53
Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology (2001) 1.51
Association of hepatic vein obstruction and coeliac disease in North African subjects. J Hepatol (1994) 1.51
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Hepatol (1993) 1.49
Peliosis hepatis in recipients of renal transplants. Gut (1978) 1.48
Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet (1981) 1.47
Protein F. A novel F(ab)-binding factor, present in normal liver, and largely released in the digestive tract during hepatitis. J Immunol (1990) 1.47
Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol (1996) 1.46
Chronic hepatitis in kidney allograft recipients. Lancet (1990) 1.45
Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C. Ann Intern Med (1997) 1.44
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med (1992) 1.44